Halozyme Therapeutics (HALO) Tops Q3 EPS by 6c; Raises Outlook
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $111.49 +1.65%
EPS Growth %: +30.8%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69. Halozyme Therapeutics sees FY2020 revenue of $250-260 million, versus the consensus of $235.94 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Barclays says AI trade is maturing, favors greater diversification
- Halozyme prices $1.3B convertible notes offering due 2033
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
